35 results
8-K
EX-10.1
RCEL
AVITA Medical Inc
18 Oct 23
Preliminary commercial revenue of $13.5 million for the third quarter 2023; full year 2023 guidance confirmed
9:07am
, customer and prospective customer lists and information, and supplier and prospective supplier lists and information, research and development … services, should have its licensure, clearance(s), provider or supplier number, or accreditation suspended, revoked, or limited in any way, or any
10-KT
EX-10.11
RCEL
AVITA Medical Inc
28 Feb 22
Annual report (with FYE transition)
4:11pm
) use Confidential Information to solicit or use any other unlawful means to induce or influence any supplier, customer, agent, consultant or other person
10-KT
EX-10.18
eelre63n
28 Feb 22
Annual report (with FYE transition)
4:11pm
10-KT
r5uznp
28 Feb 22
Annual report (with FYE transition)
4:11pm
10-KT
EX-10.15
qfnnyw8ypv857
28 Feb 22
Annual report (with FYE transition)
4:11pm
10-KT
EX-10.16
zup81
28 Feb 22
Annual report (with FYE transition)
4:11pm
10-KT
EX-10.17
n8lk7sjpoz6xin9dya4h
28 Feb 22
Annual report (with FYE transition)
4:11pm
10-KT
EX-10.14
s2y7k8ap7dg yvipg6
28 Feb 22
Annual report (with FYE transition)
4:11pm
8-K
EX-10.1
3j6pwe08laj808
24 Mar 21
AVITA Medical, Inc. Names Michael Holder as Chief Financial Officer
11:47am
8-K
EX-10.1
zcyoyaago974uqvgl3
2 Dec 20
AVITA Therapeutics Appoints Kathy McGee as Chief Operating Officer
11:01am